Skip to main content
    Z

    Zenas BioPharma, Inc. Common Stock (ZBIO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $27.75
    -0.18 (-0.64%)

    Market Cap: $1.89B

    Last updated: Nov 17, 2026 at 4:33 PM ET

    Zenas BioPharma, Inc. Common Stock (ZBIO) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Zenas BioPharma, Inc. Common Stock (ZBIO) has a market cap of $1.89B and an enterprise value of $2.02B. It kept -2580.04% of revenue as net income over the last 12 months. Its share count is up 56.90% from a year earlier.

    Total Valuation

    Enterprise value is 6.42% above the market cap, as debt exceeds cash.

    Market Cap$1.89B
    Enterprise Value$2.02B
    Latest price (Nov 17, 2026)$27.75

    Key Dates

    The next earnings report is expected on Mar 15, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 15, 2027 (expected)
    Last Earnings DateNov 5, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 4.81% in the quarter ended Sep 30, 2026 and grew 193.14% a year over 2 years.

    Shares Outstanding66.15M
    Shares Change (YoY)+56.90%
    Shares Change (QoQ)+4.81%
    Share Count Growth (2Y CAGR)+193.14%

    Valuation Ratios

    Sales and book value multiples are 166.9x and 8.6x.

    P/S Ratio166.9x
    Forward P/S85.1x
    P/B Ratio8.6x

    Price Statistics

    The stock is down 20.71% over 52 weeks and trades 2.22% below its 50-day average.

    Beta (1Y)0.72
    52-Week Change-20.71%
    1-Month Change+3.89%
    3-Month Change-11.20%
    6-Month Change+55.55%
    Total Return (1Y)-20.71%
    Return vs SPY (1Y)-34.92%
    Max Drawdown (1Y)-64.79%
    Max Drawdown (3Y)-74.96%
    Sharpe Ratio (1Y)-0.25
    Correlation with SPY (1Y)0.09
    50-Day Average$28.38
    200-Day Average$25.44
    52-Week Range$13.50 to $44.60
    RSI (14 Days)48.7
    Average Volume (20 Days)497.63K

    Price chart

    Financial Position

    Current assets cover 9.42x current liabilities, and total debt is 1.41x shareholder equity.

    Current Ratio9.42x
    Quick Ratio9.42x
    Debt / Equity1.41x
    Interest Coverage-15.79x

    Returns and Efficiency

    Return on invested capital is -104.29% and return on equity is -255.20% over the last 12 months.

    Return on Equity (ROE)-255.20%
    Return on Assets (ROA)-80.24%
    Return on Invested Capital (ROIC)-104.29%
    Return on Capital Employed (ROCE)-87.31%
    Asset Turnover0.04x

    Scores

    ZBIO has an Altman Z-Score of -1.47, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Altman Z-Score-1.47
    Altman Z ZoneDistress
    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue of $21.00M over the last 12 months is up 40.00% from the 12 months before.

    Revenue$21.00M
    Revenue Growth (YoY)+40.00%
    Gross Profit$10.99M
    Operating Income-$526.40M
    Pretax Income-$541.54M
    Net Income-$541.81M
    EBIT-$533.63M
    Reported EPS (TTM)-$6.27

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 31.44% of the $675.22M in total assets.

    Cash and Equivalents$177.78M
    Total Debt$299.36M
    Net Debt$121.58M
    Net Debt Per Share$1.84
    Working Capital$539.40M
    Shareholder Equity$212.31M
    Book Value Per Share$3.21
    Total Assets$675.22M
    Total Liabilities$462.91M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$242.83M
    FCF Per Share-$4.19
    Depreciation and Amortization$3.43M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -2506.68%.

    Gross Margin52.33%
    Operating Margin-2506.68%
    Pretax Margin-2578.76%
    Net Margin-2580.04%
    EBIT Margin-2541.08%

    Dividends and Yields

    ZBIO does not pay a dividend.

    Buyback Yield-19.91%
    Shareholder Yield-19.91%

    Peer Position

    Against 7 similar companies, ZBIO has the highest P/S.

    P/S Ratio166.9x vs 6.8x median
    ROIC-104.29% vs -18.68% median
    Revenue Growth (Trailing 4 Quarters, YoY)+40.00% vs +33.55% median

    Competitors compared

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About ZBIO

    What is ZBIO's market cap?

    Zenas BioPharma, Inc. Common Stock has a market cap of $1.89B. Its enterprise value, which adds debt and subtracts cash, is $2.02B.

    How many shares of ZBIO are outstanding?

    Zenas BioPharma, Inc. Common Stock has 66.15M shares outstanding. The count is up 56.90% from a year earlier.

    Does ZBIO pay a dividend?

    No. Zenas BioPharma, Inc. Common Stock does not pay a dividend.

    How much debt does ZBIO have?

    Zenas BioPharma, Inc. Common Stock has $299.36M of total debt and $177.78M of cash and equivalents, a net debt position of $121.58M.